drugset / Trial / NCT03083171
Adrecizumab-LPS Study
RandomizedParallel-groupQuadruple-blindTreatment
Summary
In this randomized, double-blind, placebo-controlled study, either a single dose of Adrecizumab (0.5, 2.0 or 8.0 mg/kg) or placebo will be administrated to 24 healthy male volunteers during experimental endotoxemia.
Timeline
- Start
- 2017-01-04
- Primary completion
- 2017-05-24
- Completion
- 2017-05-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ENIBARCIMAB | Monoclonal antibody | 0.5 mg/kg | Intravenous |
| Comparator | ENIBARCIMAB | Monoclonal antibody | 2 mg/kg | Intravenous |
| Comparator | ENIBARCIMAB | Monoclonal antibody | 8 mg/kg | Intravenous |
Indications
No indication recorded.